Bristol Myers' Growth Portfolio Offsets Legacy Drug Declines

Bristol Myers Squibb (BMY) announced that its growth portfolio now accounts for more than half of the company's revenue, driven by strong performance of Reblozyl, Breyanzi, and Cobenfy. This shift is helping to offset the ongoing decline in sales of older drugs.

Growth Portfolio Details

The growth portfolio includes key drugs such as:

• Reblozyl: for anemia treatment.
• Breyanzi: a CAR-T cell therapy for lymphomas.
• Cobenfy: a new drug for schizophrenia.

These drugs have recorded strong sales growth, raising the growth portfolio's share to over 50% of total revenue.

Legacy Drug Challenges

Bristol Myers faces declining sales of older drugs like Eliquis and Opdivo due to patent expirations and increased competition. However, the growth portfolio's expansion is helping to mitigate this impact.

What This Means for Investors

This shift indicates that Bristol Myers is successfully diversifying its revenue sources away from legacy drugs. Investors may view this development positively, but should monitor the sustainability of new drug growth and its ability to fully offset the decline.